Clinical trials: Hormone-Resistant Prostate Cancer
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Saracatinib in Treating Patients With Prostate Cancer
This randomized phase II clinical trial is studying how well saracatinib works in treating patients with prostate cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01267266
- Testing
- saracatinib
- Where
- 15 sites in United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms
A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer
This study is being offered to patients who have hormone resistant prostate cancer (HRPC). This means that their prostate cancer is no longer responding to standard hormonal therapy.
- Trial name
- OTT10-06 (NCT01545882)
- Testing
- Degarelix
- Where
- 3 sites in Canada
- Volunteers
- 5 people
- Sponsor
- Ottawa Hospital Research Institute
Prostate Cancer
Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00976755
- Testing
- everolimus
- Where
- 13 sites in Switzerland
- Volunteers
- 37 people
- Sponsor
- Swiss Cancer Institute
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer
This randomized pilot phase I trial studies the side effects of dietary fat levels and abiraterone acetate uptake in patients with metastatic hormone-resistant prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01913015
- Testing
- abiraterone acetate, dietary intervention, pharmacological study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- OHSU Knight Cancer Institute
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
In this study researcher want to learn more about the overall survival in patients suffering from prostate gland cancer which spread outside the prostate to other parts of the body who received either a novel anti-hormone therapy…
- Trial name
- PHENIX (NCT03896984)
- Testing
- Radium-223 (Xofigo, BAY88-8223), Abiraterone, Enzalutamide
- Where
- United States
- Volunteers
- 346 people
- Sponsor
- Bayer
Prostate Cancer
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
Enthuse M0 is a large phase III clinical trial studying the efficacy of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC).
- Trial name
- ENTHUSE M0 (NCT00626548)
- Testing
- ZD4054, Palcebo
- Where
- 322 sites in United States, Argentina and 37 more
- Volunteers
- 2,577 people
- Sponsor
- AstraZeneca
Metastatic Castration-resistant Prostate Cancer, Adenocarcinoma of the Prostate
Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
The objective of this clinical study is to evaluate the effectiveness and safety of selegiline plus docetaxel therapy compared to the standard of care - docetaxel therapy - among patients diagnosed with metastatic…
- Trial name
- NCT04586543
- Testing
- Selegiline, Docetaxel
- Where
- Hungary
- Volunteers
- 110 people
- Sponsor
- László Mangel
Advanced Cancer
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
This is a two part study of the drug MK-8669 (ridaforolimus) given with MK-2206 or MK-0752. In Part A of the study, the preliminary maximum tolerated dose (MTD) of the drug combinations will be found by giving sequentially higher…
- Trial name
- NCT01295632
- Testing
- ridaforolimus, MK-0752, MK-2206
- Volunteers
- 65 people
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Metastatic Cancer, Prostate Cancer
Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01160705
- Testing
- docetaxel, RNA analysis, reverse transcriptase-polymerase chain reaction
- Where
- 5 sites in Ireland
- Volunteers
- 73 people
- Sponsor
- Cancer Trials Ireland
Prostate Cancer Metastatic, Advanced Breast Cancer
Safety and Pharmacokinetics of ODM-209
The purpose of this first-in-human study is to evaluate safety and tolerability of ODM-209 and find the dose of ODM-209.
- Conditions
- Prostate Cancer Metastatic, Advanced Breast Cancer, Castration-resistant Prostate Cancer, Metastatic Breast Cancer
- Trial name
- STESIDES (NCT03878823)
- Testing
- ODM-209
- Where
- 4 sites in Denmark, Finland and 1 more
- Volunteers
- 38 people
- Sponsor
- Orion Corporation, Orion Pharma
Hormone Resistant Prostate Cancer, Metastatic Prostate Cancer
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
we propose to randomize patients with hormone resistant prostate cancer between docetaxel/estramustine/prednisone and docetaxel/prednisone in a phase II study. The principal endpoint will be the efficacy in term of PSA response.
- Trial name
- NCT00541281
- Testing
- docetaxel, estramustine, prednisone
- Where
- 19 sites in Belgium, Luxembourg
- Volunteers
- 150 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Prostate Cancer, Bone Metastases
Evaluation of Tolerance and Efficacy Retrospective Data of XOFIGO
Since 13 November 2013, XOFIGO has been authorised on the European zone for the treatment of patients with prostate cancer, in the phase of resistance to castration, with symptomatic bone metastases.
- Conditions
- Prostate Cancer, Bone Metastases, Hormone-resistant Prostate Cancer
- Trial name
- XOFIGO (NCT04516707)
- Testing
- clinical database
- Where
- 8 sites in France
- Volunteers
- 67 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Hypogonadism, Metabolic Syndrome
Androgen Deprivation Therapy Study
The purpose of this study is to examine the link between low testosterone and insulin resistance/diabetes in men undergoing androgen deprivation therapy for prostate cancer.
- Conditions
- Hypogonadism, Metabolic Syndrome, Diabetes, Inflammation
- Trial name
- ADT (NCT00743327)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute on Aging (NIA)
Castration-resistant Prostate Cancer
Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer
This study is comparing the safety and effectiveness of abiraterone acetate alone, followed by the addition of prednisone (when the participant's disease worsens or the physician feels it would lessen symptoms of toxicity) versus…
- Trial name
- NCT02025010
- Testing
- abiraterone acetate
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dana-Farber Cancer Institute
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/ fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) in measuring response to a drug, radium Ra 223…
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma
- Trial name
- NCT02429804
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Fluorine F 18 Sodium Fluoride
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Adenocarcinoma of the Prostate, Bone Metastases
BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
BMS-275291 may stop the growth of prostate cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Conditions
- Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT00040755
- Testing
- rebimastat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Hormone Refractory Prostate Cancer
PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
This study will evaluate the safety of PD-1 knockout engineered T cells in treating castration resistant prostate cancer (CRPC). Blood samples will also be collected for research purposes.
- Trial name
- NCT02867345
- Testing
- PD-1 Knockout T Cells, Cyclophosphamide, IL-2
- Where
- China
- Sponsor
- Peking University
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
This randomized phase II trial studies how well docetaxel works when given with or without ascorbic acid in treating patients with prostate cancer that has spread to other places in the body.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT02516670
- Testing
- Ascorbic Acid, Docetaxel, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate
PROCARE - PROstate Cancer Real World Evidence Registry
The aim of this registry study with long-term follow-up is to record the course of therapy and disease in patients with recurrent and metastatic prostate cancer.
- Conditions
- Prostate Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate, Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Trial name
- PROCARE (NCT06835218)
- Where
- 53 sites in Germany
- Volunteers
- 5,000 people
- Sponsor
- UroTrials Company (GmbH)